Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eishi Baba

Showing results (161-170 of 189) with videos related to

Pageof 19
Sort By:
Journal of Clinical Medicine|November 13, 2021
Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients?Eijiro Shimada, Makoto Endo, Yoshihiro Matsumoto, et al.
The Oncologist|September 13, 2017
Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational StudyToshikazu Moriwaki, Shota Fukuoka, Hiroya Taniguchi, et al.
International Journal of Clinical Oncology|June 21, 2024
Effectiveness and safety of primary prophylaxis with G-CSF for patients with Ewing sarcomas: a systematic review for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical OncologyTakeshi Hirose, Mamoru Ito, Kenji Tsuchihashi, et al.
International Journal of Clinical Oncology|June 12, 2024
Primary prophylaxis with G-CSF for patients with non-round cell soft tissue sarcomas: a systematic review for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical OncologyTakeshi Hirose, Mamoru Ito, Kenji Tsuchihashi, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|November 1, 2022
Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in JapanMasahiko Aoki, Shigenori Kadowaki, Naoki Takahashi, et al.
European Journal of Cancer (Oxford, England : 1990)|March 25, 2026
Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST)Yosuke Kito, Kentaro Yamazaki, Hirokazu Shoji, et al.
International Journal of Clinical Oncology|March 18, 2024
Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncologyTomoya Maeda, Yuho Najima, Yutaro Kamiyama, et al.
International Journal of Clinical Oncology|June 20, 2024
Effectiveness and safety of primary prophylaxis with G-CSF during chemotherapy for invasive breast cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the Use of G-CSF 2022Kazuki Nozawa, Yukinori Ozaki, Tetsuhiro Yoshinami, et al.
International Journal of Clinical Oncology|May 16, 2024
Effectiveness and safety of granulocyte colony-stimulating factor priming regimen for acute myeloid leukemia: A systematic review and meta-analysis of the Clinical Practice Guideline for the use of G-CSF 2022 from the Japan Society of Clinical OncologyYuho Najima, Tomoya Maeda, Yutaro Kamiyama, et al.
International Journal of Clinical Oncology|May 2, 2024
Therapeutic use of granulocyte colony-stimulating factor (G-CSF) in patients with febrile neutropenia: a comprehensive systematic review for clinical practice guidelines for the use of G-CSF 2022 from the Japan Society of Clinical OncologyKenji Tsuchihashi, Mamoru Ito, Yuta Okumura, et al.
Pageof 19

Showing results (161-170 of 189) with videos related to

Sort By:
Pageof 19
Journal of Clinical Medicine|November 13, 2021
Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients?Eijiro Shimada, Makoto Endo, Yoshihiro Matsumoto, et al.
The Oncologist|September 13, 2017
Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational StudyToshikazu Moriwaki, Shota Fukuoka, Hiroya Taniguchi, et al.
International Journal of Clinical Oncology|June 21, 2024
Effectiveness and safety of primary prophylaxis with G-CSF for patients with Ewing sarcomas: a systematic review for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical OncologyTakeshi Hirose, Mamoru Ito, Kenji Tsuchihashi, et al.
International Journal of Clinical Oncology|June 12, 2024
Primary prophylaxis with G-CSF for patients with non-round cell soft tissue sarcomas: a systematic review for the Clinical Practice Guidelines for the Use of G-CSF 2022 of the Japan Society of Clinical OncologyTakeshi Hirose, Mamoru Ito, Kenji Tsuchihashi, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|November 1, 2022
Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in JapanMasahiko Aoki, Shigenori Kadowaki, Naoki Takahashi, et al.
European Journal of Cancer (Oxford, England : 1990)|March 25, 2026
Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST)Yosuke Kito, Kentaro Yamazaki, Hirokazu Shoji, et al.
International Journal of Clinical Oncology|March 18, 2024
Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncologyTomoya Maeda, Yuho Najima, Yutaro Kamiyama, et al.
International Journal of Clinical Oncology|June 20, 2024
Effectiveness and safety of primary prophylaxis with G-CSF during chemotherapy for invasive breast cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the Use of G-CSF 2022Kazuki Nozawa, Yukinori Ozaki, Tetsuhiro Yoshinami, et al.
International Journal of Clinical Oncology|May 16, 2024
Effectiveness and safety of granulocyte colony-stimulating factor priming regimen for acute myeloid leukemia: A systematic review and meta-analysis of the Clinical Practice Guideline for the use of G-CSF 2022 from the Japan Society of Clinical OncologyYuho Najima, Tomoya Maeda, Yutaro Kamiyama, et al.
International Journal of Clinical Oncology|May 2, 2024
Therapeutic use of granulocyte colony-stimulating factor (G-CSF) in patients with febrile neutropenia: a comprehensive systematic review for clinical practice guidelines for the use of G-CSF 2022 from the Japan Society of Clinical OncologyKenji Tsuchihashi, Mamoru Ito, Yuta Okumura, et al.
Pageof 19